This implies that SGK1 and Nedd4L are involved in the development of hyperglycemia-induced cardiomyopathy, future studies are warranted to validate whether targeting SGK1 and Nedd4L could provide a solution for the clinical treatment of diabetic cardiomyopathy or not [108]. This evidence concerns the gene SGK1 and cardiomyopathy.